2015 Fiscal Year Final Research Report
In vivo evaluation of macromolecular antitumor agent, P-THP, in pancreatic cancer
| Project/Area Number |
26860031
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | すい臓がん / ピラルビシン / 高分子ポリマー / HPMA |
|---|
| Outline of Final Research Achievements |
Many conjugates of water-soluble polymers with biologically active molecules were developed. However, therapeutic effects of these conjugates do not depend only on the structures and properties of the polymer carriers; they are strongly influenced by properties and mechanisms of action of the attached drugs. Pirarubicin (THP), a tetrahydropyranyl derivative of doxorubicin (DOX), demonstrated more rapid cellular internalization and potent cytotoxicity than DOX. Here, we conjugated the THP or DOX to HPMA polymer via a hydrazone bond. The polymer prodrugs P-THP and P-DOX, respectively, had comparable hydrodynamic sizes and drug loading. Compared with P-DOX, P-THP showed approximately 10 times greater cellular uptake and a cytotoxicity. No significant difference occurred in the tumor drug concentration during 6-24 h after drug administration. Antitumor activity against xenograft human pancreatic tumor (SUIT2) in mice was greater for P-THP than for P-DOX.
|
| Free Research Field |
ドラッグデリバリーシステム
|
